GSKure

Company Overview

Snapshot

Founded in January 2016 by Hagit Eldar- Finkelman, Ph.D., GSKure operates with 1–10 employees. The company focuses on drug discovery and design, particularly for neurogenetic disorders. In February 2016, GSKure was part of the first class of neurotech startups to graduate from Brainnovations.

Business overview

GSKure is an IP-based company specializing in the development of innovative proprietary GSK-3 peptide inhibitor drug candidates. Its Kure products are designed to target a unique substrate binding site on the GSK-3 protein, offering improved selectivity and lower toxicity compared to traditional ATP-competitive inhibitors. This novel substrate-competitive inhibitor (SCI) strategy aims to provide significant advantages for clinical practice in treating human diseases. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development, serving markets such as the United States.

Strategic signal

In February 2016, GSKure graduated from Brainnovations as part of its first class of neurotech startups. This event signals early validation of the company's innovative approach to neurogenetic disorder treatments and its potential within the burgeoning neurotech landscape, indicating a foundational step in its development and market entry.

Company Intelligence Q&A

What is GSKure's core focus?

GSKure is an IP-based company focused on developing innovative proprietary GSK-3 peptide inhibitor drug candidates for treating neurogenetic disorders.

When was GSKure founded?

GSKure was founded in January 2016.

Who is the founder of GSKure?

Hagit Eldar- Finkelman, Ph.D. is the Founder & CEO of GSKure.

What is the primary technology behind GSKure's products?

GSKure's Kure products are based on a novel design of compounds that target a unique region at the GSK-3 protein surface, known as the substrate binding site, utilizing substrate-competitive inhibitors (SCIs).

What was a significant early milestone for GSKure?

In February 2016, GSKure graduated as part of the first class of neurotech startups from Brainnovations.